ADXS stock forecast
Our latest prediction for Advaxis, Inc.'s stock price was made on the Feb. 2, 2018 when the stock price was at 2.90$.
In the short term (2weeks), ADXS's stock price should outperform the market by 0.33%. During that period the price should oscillate between -8.37% and +11.13%.
In the medium term (3months), ADXS's stock price should outperform the market by 7.31%. During that period the price should oscillate between -19.75% and +37.92%.Get email alerts
Create a solid portfolio with ADXS
About Advaxis, Inc.
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
At the moment the company generates 7M USD in revenues.
On its last earning announcement, the company reported a loss of -1.57$ per share.
The book value per share is 0.48$
Three months stock forecastFeb. 2, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|